Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration.
The refillable device, which is slightly longer than a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy.
Get the full story at our sister site, Drug Delivery Business News.